Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on Tobevibart and Elebsiran for Patients with Chronic Hepatitis D Virus Infection

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying a condition known as Chronic Hepatitis D Virus (HDV) Infection. The study will evaluate a combination treatment using two investigational medications, Tobevibart and Elebsiran. Tobevibart is a type of protein called a monoclonal antibody, which is designed to target specific parts of the virus. Elebsiran is a nucleic acid-based treatment that aims to interfere with the virus's ability to replicate.

The purpose of this study is to assess how effective and safe the combination of Tobevibart and Elebsiran is for people with chronic HDV infection. Participants in the study will receive these medications through injections under the skin. The study will compare the effects of starting the treatment immediately versus delaying it. Throughout the study, participants will have regular check-ups to monitor their health and the virus's response to the treatment.

The study will last for several years, with participants being observed at different intervals to see how the treatment affects the virus and their liver health over time. The goal is to see if the combination of Tobevibart and Elebsiran can reduce the amount of virus in the body and improve liver function. Participants will be closely monitored for any side effects or changes in their condition during the study period.

The research process

The trial runs in 7 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial visit

    Upon joining the study, an initial visit is scheduled. During this visit, eligibility is confirmed based on specific criteria such as age, health condition, and previous medical history related to chronic hepatitis D virus (HDV) infection.

    A detailed explanation of the study, including its purpose and procedures, is provided. Consent is obtained to ensure understanding and agreement to participate.

  2. Step 2

    Baseline assessments

    Baseline assessments are conducted to gather initial health data. This includes blood tests to measure HDV RNA levels and liver function tests to assess alanine aminotransferase (ALT) levels.

    Additional assessments may include liver imaging to evaluate liver condition and other relevant health checks.

  3. Step 3

    Treatment initiation

    The treatment phase begins with the administration of the study medications, tobevibart and elebsiran. These medications are given as injections under the skin (subcutaneous use).

    The dosage and frequency of administration are determined by the study protocol, and participants are informed of the schedule.

  4. Step 4

    Regular follow-up visits

    Regular follow-up visits are scheduled to monitor health and response to treatment. These visits include blood tests to measure HDV RNA and ALT levels, as well as assessments of any side effects or adverse events.

    The frequency of these visits is determined by the study protocol, and participants are informed of the schedule.

  5. Step 5

    Mid-study evaluation

    A mid-study evaluation is conducted to assess progress. This includes a comprehensive review of health data collected during the study, such as changes in HDV RNA and ALT levels.

    Adjustments to the treatment plan may be made based on the evaluation results.

  6. Step 6

    End of treatment phase

    The treatment phase concludes after a specified duration, as outlined in the study protocol. Final assessments are conducted to evaluate the overall effectiveness and safety of the treatment.

    Participants are informed of the results and any further steps, such as continued monitoring or additional treatment options.

  7. Step 7

    Long-term follow-up

    Long-term follow-up visits are scheduled to monitor health after the treatment phase. These visits may continue for several years to assess the long-term effects of the treatment.

    Participants are informed of the schedule and any ongoing assessments required.

Who can join the trial?

6 criteria

  • Adult men and women aged 18 to 70 years at the time of signing the consent form.
  • Must have a positive test for Hepatitis D Virus (HDV) for at least 6 months before the study and a certain level of the virus in the blood at the start of the study.
  • Must have liver disease that is either not severe or is stable.
  • Must have a specific level of a liver enzyme called alanine aminotransferase (ALT) in the blood, which is higher than normal but not excessively high.
  • Must have a Body Mass Index (BMI) between 18 and 40. BMI is a measure of body fat based on height and weight.
  • Must be on certain medications for Hepatitis B Virus (HBV) for at least 12 weeks before the study or have a very low level of HBV in the blood. The medications include tenofovir alafenamide, tenofovir disoproxil fumarate, or entecavir.

Who cannot join the trial?

3 criteria

  • Patients who do not have a chronic Hepatitis D Virus (HDV) infection cannot participate. This means if you do not have a long-term infection with the Hepatitis D virus, you are not eligible.
  • Patients who are not within the specified age range cannot participate. The study is open to certain age groups only.
  • Patients who are part of a vulnerable population are not eligible. This refers to groups of people who might be at a higher risk of harm or exploitation.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Tobevibart

    is a medication being studied for its potential to help people with chronic HDV infection. HDV, or Hepatitis D Virus, is a serious liver infection. Tobevibart is designed to work by targeting the virus in the body, helping to reduce its effects and improve liver health. In this trial, researchers are looking at how well Tobevibart works when used together with another medication, and they are also checking to make sure it is safe for patients to use.

  • Elebsiran

    is another medication being tested in this study for people with chronic HDV infection. Like Tobevibart, Elebsiran aims to fight the virus that causes the infection. By using Elebsiran, researchers hope to see improvements in the health of the liver and a reduction in the symptoms of the infection. The study is also focused on understanding the safety of using Elebsiran in combination with Tobevibart, to ensure that this combination is safe for patients.

What is already known about the treatment

  • Tobevibart

    Tobevibart is administered as part of a combination therapy for chronic Hepatitis D Virus (HDV) infection. It is currently being studied in clinical trials to assess its effectiveness and safety. The main therapeutic use of Tobevibart is to help manage chronic HDV infection. At the molecular level, it works by targeting specific pathways involved in the virus's life cycle, helping to reduce the viral load in the body. Tobevibart is classified as an antiviral medication.

  • Elebsiran

    Elebsiran is used in combination with Tobevibart for the treatment of chronic Hepatitis D Virus (HDV) infection. It is under investigation in clinical trials to determine its efficacy and safety profile. The primary therapeutic indication for Elebsiran is to assist in controlling chronic HDV infection. Its mechanism of action involves interfering with the virus's ability to replicate, thereby decreasing the amount of virus in the body. Elebsiran is also classified as an antiviral drug.

Investigated diseases

Chronic Hepatitis D Virus Infection – Chronic Hepatitis D Virus (HDV) infection is a liver disease caused by the hepatitis D virus, which requires the presence of hepatitis B virus (HBV) to replicate. The disease progresses as the virus infects liver cells, leading to inflammation and damage over time. This can result in liver fibrosis, where scar tissue forms in the liver, potentially leading to cirrhosis. As the disease advances, liver function may decline, and complications such as liver stiffness and decompensated cirrhosis can occur. The infection can also increase the risk of developing hepatocellular carcinoma, a type of liver cancer. Chronic HDV infection is considered a rare disease and can significantly impact liver health over time.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-515919-22-00Protocol codeVIR-CHDV-V203Estimated enrolment120 patientsSponsorVir Biotechnology Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).